F
F. Mornex
Researcher at Aix-Marseille University
Publications - 9
Citations - 1331
F. Mornex is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Chemoradiotherapy & Gemcitabine. The author has an hindex of 8, co-authored 9 publications receiving 1179 citations.
Papers
More filters
Journal ArticleDOI
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study
Bruno Chauffert,F. Mornex,Franck Bonnetain,Ph. Rougier,Christophe Mariette,O. Bouche,J.-F. Bosset,Thomas Aparicio,Laurent Mineur,A. Azzedine,Pascal Hammel,J. Butel,N. Stremsdoerfer,Philippe Maingon,Laurent Bedenne +14 more
TL;DR: This intensive induction schedule of CHRT was more toxic and less effective than gemcitabine alone and was confirmed in a per-protocol analysis for patients who received 75% or more of the planned dose of radiotherapy.
Journal ArticleDOI
Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901
Christophe Mariette,Laetitia Dahan,F. Mornex,Emilie Maillard,Pascal-Alexandre Thomas,Bernard Meunier,Valérie Boige,Denis Pezet,William B. Robb,Valérie Le Brun-Ly,Jean-François Bosset,Jean-Yves Mabrut,Jean-Pierre Triboulet,Laurent Bedenne,Jean-François Seitz +14 more
TL;DR: Compared with surgery alone, NCRT with cisplatin plus fluorouracil does not improve R0 resection rate or survival but enhances postoperative mortality in patients with stage I or II EC.
Journal ArticleDOI
Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: Analysis of a randomized controlled phase III trial FFCD 9901.
Christophe Mariette,J.F. Seitz,Emilie Maillard,F. Mornex,Pascal Thomas,Jean-Luc Raoul,Valérie Boige,Denis Pezet,C. Genet,Laurent Bedenne,Federation Francaise de Cancerologie Digestive +10 more
TL;DR: Resection remains the best treatment for carcinoma of the esophagus regarding local control but local recurrence, distant metastatis and poor survival remain an issue after surgery after surgery.
Journal ArticleDOI
Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study
Bruno Chauffert,F. Mornex,F. Bonnetain,J.-P. Triboulet,O. Bouche,Ph. Rougier,J.-F. Bosset,Thomas Aparicio,F. Masskouri,Laurent Bedenne +9 more
TL;DR: This randomized trial evaluated whether initial CHRT adds to modern gemcitabine in term of Overall Survival (OS) in patients with locally advanced non metastatic pancreatic cancer and stopped before the planned inclusion due to lower survival with initial ChRT when compared to G alone.
Journal ArticleDOI
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer.
Emmanuel Mitry,Pascal Hammel,Gael Deplanque,F. Mornex,Philippe Lévy,Jean-François Seitz,Alain Moussy,Jean-Pierre Kinet,Olivier Hermine,Philippe Rougier,Eric Raymond +10 more
TL;DR: The efficacy and safety of masitinib combined with gemcitabine are encouraging, with extended survival and median TTP that support initiation of a phase 3 trial in patients with advanced pancreatic cancer.